

Pembrolizumab

Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a [humanized antibody](#) used in cancer [immunotherapy](#). This includes treating [melanoma](#), [lung cancer](#), [head and neck cancer](#), [Hodgkin lymphoma](#), and stomach cancer. It is given by slow injection into a vein.

anti-[PD-1](#) drug (monoclonal antibody to PD-1 programmed cell death receptor): [pembrolizumab](#) (Keytruda) approved for advanced or unresectable melanoma not responding to other drugs ¹⁾.

Pembrolizumab for non-Small-cell lung cancer

[Pembrolizumab for non-Small-cell lung cancer](#).

Pembrolizumab for glioblastoma

[Pembrolizumab for glioblastoma](#).

References

¹⁾
U.S. Food and Drug Administration (FDA). FDA approves Keytruda for advanced melanoma. 2014.
<https://wayback.archive-it.org/7993/20170112023823/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm>

From:
<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:
<https://neurosurgerywiki.com/wiki/doku.php?id=pembrolizumab>

Last update: **2024/06/07 03:00**

